Your browser doesn't support javascript.
loading
Montrer: 20 | 50 | 100
Résultats 1 - 4 de 4
Filtrer
2.
Infez Med ; 23(2): 117-24, 2015 Jun.
Article de Anglais | MEDLINE | ID: mdl-26110291

RÉSUMÉ

The aim of this survey was to describe the incidence, epidemiology, microbiology, risk factors and outcome of medical care related laboratory-confirmed bloodstream infections (LCBIs) observed during a twelve-month prospective study in a Paediatric Teaching Hospital in Turin, Italy. Inclusion criteria were clinical signs of sepsis and positivity of one or more of the following tests: blood culture, polymerase chain reaction for bacterial and fungal DNA on blood, and culture on intravascular device tips. In all, 140 episodes of sepsis were documented in 131 children: 37 (26.4%) were healthcare outpatient-associated, 91 (65.0%) healthcare-associated and 12 (8.6%) community-acquired. The overall incidence of healthcare-associated LCBIs was 13.6/1,000 hospitalized patients and incidence density 1.4/1,000 inpatient days. The overall mortality was 3.9%. Forty-seven (36.7%) episodes involved newborns and 107 (83.6%) episodes were observed in children with an indwelling central venous catheter. Coagulase-negative staphylococci (26.8%), Staphylococcus aureus (15.2%), Escherichia coli (8.7%) and Candida spp. (7.2%) were responsible for the majority of cases. 9.5% of S. aureus isolates were methicillin-resistant and 6.5% of Gram negatives were extended-spectrum beta-lactamase-producing. Incidence and epidemiology of medical care related LCBIs were similar to the existing literature data. LCBIs caused by antibiotic-resistant microorganisms were fewer and mortality rate was lower. Most of the LCBIs recorded involved newborns and oncological children.


Sujet(s)
Bactériémie/diagnostic , Bactériémie/microbiologie , Infection croisée/complications , Pédiatrie , Infections à staphylocoques/complications , Staphylococcus aureus/pathogénicité , Antibactériens/usage thérapeutique , Bactériémie/traitement médicamenteux , Bactériémie/épidémiologie , Enfant , Enfant d'âge préscolaire , Multirésistance bactérienne aux médicaments , Femelle , Hôpitaux pédiatriques , Hôpitaux d'enseignement , Humains , Incidence , Nourrisson , Nouveau-né , Unités de soins intensifs pédiatriques , Italie/épidémiologie , Mâle , Staphylococcus aureus résistant à la méticilline/isolement et purification , Études prospectives , Facteurs de risque , Staphylococcus aureus/isolement et purification
3.
Vaccine ; 32(35): 4466-4470, 2014 Jul 31.
Article de Anglais | MEDLINE | ID: mdl-24962760

RÉSUMÉ

OBJECTIVE: To evaluate the effectiveness of seasonal influenza vaccine in preventing Emergency Department (ED) visits and hospitalisations for influenza like illness (ILI) in children. METHODS: We conducted a test negative case-control study during the 2011-2012 and 2012-2013 influenza seasons. Eleven paediatric hospital/wards in seven Italian regions participated in the study. Consecutive children visiting the ED with an ILI, as diagnosed by the doctor according to the European Centre for Disease Control case definition, were eligible for the study. Data were collected from trained pharmacists/physicians by interviewing parents during the ED visit (or hospital admission) of their children. An influenza microbiological test (RT-PCR) was carried out in all children. RESULTS: Seven-hundred and four children, from 6 months to 16 years of age, were enrolled: 262 children tested positive for one of the influenza viruses (cases) and 442 tested negative (controls). Cases were older than controls (median age 46 vs. 29 months), though with a similar prevalence of chronic conditions. Only 25 children (4%) were vaccinated in the study period. The overall age-adjusted vaccine effectiveness (VE) was 38% (95% confidence interval -52% to 75%). A higher VE was estimated for hospitalised children (53%; 95% confidence interval -45% to 85%). DISCUSSION: This study supports the effectiveness of the seasonal influenza vaccine in preventing visits to the EDs and hospitalisations for ILI in children, although the estimates were not statistically significant and with wide confidence intervals. Future systematic reviews of available data will provide more robust evidence for recommending influenza vaccination in children.


Sujet(s)
Vaccins antigrippaux/administration et posologie , Vaccins antigrippaux/immunologie , Grippe humaine/anatomopathologie , Grippe humaine/prévention et contrôle , Adolescent , Études cas-témoins , Enfant , Enfant d'âge préscolaire , Services des urgences médicales/statistiques et données numériques , Femelle , Hospitalisation/statistiques et données numériques , Humains , Nourrisson , Italie/épidémiologie , Mâle , Résultat thérapeutique
4.
Infez Med ; 20(3): 176-81, 2012 Sep.
Article de Anglais | MEDLINE | ID: mdl-22992557

RÉSUMÉ

Introduction. Invasive bacterial diseases continue to represent a significant burden in paediatric age, and the emergence of previously secondary bacteria and antibiotic-resistant strains requires a continuous surveillance. Materials and methods. A one-year prospective survey on laboratory confirmed community-acquired bloodstream infections (CA-LBSIs) cases admitted to an Italian tertiary specialistic paediatric Hospital. Results. Twelve cases were documented, with an incidence rate of 0.39/1,000 admissions to the Emergency Department, and of 2.9/1,000 hospitalizations to general and specialized wards. Mean age at diagnosis was 5.2 +/- 5.9 years, with 58.3% of episodes regarding children younger than years. Six episodes were caused by Gram positive and six by Gram negative bacteria, with potential vaccine-preventable pathogens responsible of 50% of CA-LBSIs. Empiric antibiotic therapy prescribed at admission was found appropriate to microbiological results in the totality of cases and administered for a mean time of 17.7 +/- 10.1 days. No resistant strains were found. All patients had a good outcome. Conclusions. Prompt collection of samples for microbiological tests together with the rapid institution of empiric antibiotic therapy are essential for the correct management of CA-LBSIs in paediatric patients. Implementation of vaccinations against the major responsible pathogens remains the most important prevention strategy.


Sujet(s)
Antibactériens/usage thérapeutique , Bactériémie/traitement médicamenteux , Bactériémie/épidémiologie , Patients hospitalisés/statistiques et données numériques , Adolescent , Bactériémie/diagnostic , Bactériémie/microbiologie , Bactériémie/prévention et contrôle , Enfant , Enfant d'âge préscolaire , Infections communautaires/traitement médicamenteux , Infections communautaires/épidémiologie , Femelle , Bactéries à Gram négatif/isolement et purification , Bactéries à Gram positif/isolement et purification , Enquêtes sur les soins de santé , Hôpitaux pédiatriques , Hôpitaux universitaires , Humains , Incidence , Nourrisson , Italie/épidémiologie , Mâle , Études prospectives , Facteurs de risque , Résultat thérapeutique
SÉLECTION CITATIONS
DÉTAIL DE RECHERCHE